Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Saad Usmani

Myeloma · MSK

View

Dr. Marc Braunstein

Myeloma · NYU Grossman Long Island

View

Dr. Talal Hilal

Lymphoma · Mayo Clinic College of Medicine

View

Dr. Midhun Malla

GI Oncology · UAB

View

Dr. Kamal Menghrajani

Leukemia · MGH

View

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Gideon Dosunmu

GI Oncology · Emory Hospital Midtown

View

Dr. Pavlos Msaouel

GU Oncology · MD Anderson Cancer Center

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. Naval Daver

Leukemia · MD Anderson Cancer Center

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    CHDr. Craig Hofmeister

    Dr. Craig Hofmeister

    Hematology & Oncology · Myeloma
    Emory University
    craig
    Atlanta, GA, USA

    Research

    Alnuctamab, a bivalent B-cell maturation antigen-targeting T cell engager for patients with relapsed or refractory multiple myeloma: results from a phase 1, first-in-human study

    2026

    Via Leukemia

    Research

    The Evolution of Chimeric Antigen Receptor T-Cell, Bispecific Antibodies and Antibody-Drug Conjugates for the Treatment of Multiple Myeloma

    2026

    Via Clinical Lymphoma, Myeloma & Leukemia

    Research

    Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects

    2025

    Via Journal of Hematology & Oncology

    Research

    Efficacy and safety of daratumumab in intermediate/high-risk smoldering multiple myeloma: final analysis of CENTAURUS

    2025

    Via Blood

    Research

    Persistent opioid use is associated with a shorter myeloma survival

    2025

    Via Supportive Care in Cancer

    Research

    Immune-aging is linked to clinical malignancy, racial ancestry, and vaccine responses in myeloma

    2025

    Via Blood Advances

    Research

    Stem Cell Mobilization Yields with Daratumumab and Lenalidomide-Containing Quadruplet Induction Therapy in Patients with Newly Diagnosed Multiple Myeloma: A Real-World Experience at 2 Institutes

    2025

    Via Clinical Lymphoma, Myeloma & Leukemia

    Research

    Feasibility and Safety of Outpatient Model for Administration of Bispecific Antibodies: Proceedings from an International Myeloma Society 21st Annual Meeting Oral Abstract

    2025

    Via Clinical Lymphoma, Myeloma & Leukemia

    Research

    Early CD4+ T cell proliferation and chronic T cell engagement impact myeloma outcomes following T cell engager therapy

    2025

    Via The Journal of Clinical Investigation

    Research

    Infection risk in 158 patients with relapsed/refractory multiple myeloma treated with bispecific antibodies: a single-center experience

    2025

    Via Haematologica

    Research

    Quadruplet therapy for newly diagnosed myeloma: comparative analysis of sequential cohorts with triplet therapy lenalidomide, bortezomib and dexamethasone (RVd) versus daratumumab with RVD (DRVd) in transplant-eligible patients

    2024

    Via Blood Cancer Journal

    Research

    Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunity

    2024

    Via NPJ Vaccines

    Research

    Evaluating the Impacts of CYP3A4*1B and CYP3A5*3 Variations on Pharmacokinetic Behavior and Clinical Outcomes in Multiple Myeloma Patients With Autologous Stem Cell Transplant

    2023

    Via Cancer Genomics & Proteomics

    Research

    Eliminating the monitoring period with subcutaneous daratumumab: a single-center experience

    2023

    Via Blood Cancer Journal

    Research

    Impaired SARS-CoV-2 Variant Neutralization and CD8+ T-cell Responses Following 3 Doses of mRNA Vaccines in Myeloma: Correlation with Breakthrough Infections

    2023

    Via Blood Cancer Discovery